NCT04425239View on ClinicalTrials.gov

Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

151

Participants

Timeline

Start Date

May 21, 2018

Primary Completion Date

July 2, 2021

Study Completion Date

April 3, 2022

Conditions

Colorectal Cancer Stage IV

Interventions

DRUG

Panitumumab

Continuous administation

DRUG

Panitumumab

Intermittent administation

Trial Locations (1)

80131

Istituto Nazionale Tumori di Napoli - IRCCS - Fondazione G. Pascale, Napoli

All Listed Sponsors

lead

National Cancer Institute, Naples

OTHER

NCT04425239 - Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter